NASDAQ$DNTH

Dianthus Therapeutics Inc · Q3 2020 earnings

Q3 2020 earnings ·

Headline financials

Total Revenue

$0.00

Previous: $0.00
Capital Expenditures

-$187K

Previous: -$2.91M+93.6%
Free Cash Flow

-$17.9M

Previous: -$23.9M+25.2%
Net Income

-$17.7M

Previous: -$21M+15.8%
Operating Income

-$18.4M

Previous: -$22.6M+18.8%
Gross Profit

$0.00

Previous: $0.00

Revenue & EPS history

Dianthus Therapeutics Inc · Revenue · Quarterly

$0

Q3 2020
Beat estimate in 1 of 2 quarters(50%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 15 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

+1.6%

Avg return

Earnings day

-2.3%

Avg return

5 days after

+1.9%

Avg return

30 days after

73%

11 / 15 earnings

Positive

+11.1%

Q2 2019

Best reaction

-6.1%

Q2 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.1%-2.9%-5.8%
Q4 2025+9.7%-1.7%+15.7%
Q3 2025+1.6%+10.3%+33.3%
Q2 2025-6.1%-2.4%+30.0%
Q1 2025+2.5%+0.5%-7.5%
Q3 2023+0.4%-0.5%-16.4%
Q2 2023+2.5%-1.2%-8.6%
Q3 2020-0.9%-1.4%+11.7%
Q2 2020+0.6%+0.0%-8.3%
Q1 2020+2.7%-1.3%+5.4%
Q3 2019-2.2%-13.5%+21.2%
Q2 2019+11.1%-0.8%-13.2%
Q1 2019+2.7%+9.9%-10.7%
Q3 2018-3.4%-24.7%-14.1%
Q2 2018+1.2%-4.2%-4.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro